Lipid-nanoparticle-enabled nucleic acid therapeutics for liver disorders

Area of Science:

• Hepatology
• Gene Therapy
• Nanomedicine

Background:

• Inherited liver diseases represent a significant public health concern.
• Current treatments like liver transplantation face limitations due to donor scarcity and high costs of immunosuppression.
• Nucleic acid therapy offers potential for gene repair, supplementation, and silencing.

Purpose of the Study:

• To explore lipid nanoparticles (LNPs) as an alternative delivery system for nucleic acid therapy in liver diseases.
• To discuss the applications of LNPs in protein replacement, disease mechanism restoration, and gene editing.
• To review preclinical and clinical studies evaluating LNPs as an alternative to liver transplantation.

Main Methods:

• Review of existing literature on nucleic acid therapy and lipid nanoparticle applications.
• Discussion of various nucleic acid types deliverable by LNPs (pDNA, mRNA, siRNA).
• Analysis of preclinical and clinical data for LNP-based liver disease therapies.

Main Results:

• Lipid nanoparticles can effectively deliver diverse nucleic acid payloads.
• LNPs show potential for protein replacement and restoring disease mechanisms.
• Preclinical and clinical studies demonstrate LNP efficacy as an alternative to liver transplantation.

Conclusions:

• Lipid nanoparticles are a viable and versatile platform for treating inherited liver disorders.
• LNP-mediated nucleic acid therapy presents a promising alternative to liver transplantation.
• Further clinical development of LNPs could revolutionize liver disease treatment.